Shares of United Therapeutics (UTHR) are down $41.40, or 13%, to $287.00 in pre-market trading after Insmed (INSM) announced positive topline results from its randomized, double-blind, placebo-controlled Phase 2b study evaluating the efficacy and safety of treprostinil palmitil inhalation powder, or TPIP, administered once daily in patients with pulmonary arterial hypertension.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- Liquidia price target raised to $32 from $25 at Needham
- Liquidia schedules first commercial shipment of YUTREPIA
- United Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Maintaining Market Position: United Therapeutics’ Tyvaso DPI Amidst Competition and Future Growth Prospects
- Liquidia price target raised to $23 from $20 at Wells Fargo